GlassScriptPhysician profile
Ajay Kumar Mishra
NPI 1982181731
$5,779.27
in general payments reported to CMS, 2019-2025
30 companies · $80.81 in 2025
The $80.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $347 · 2021: $1,190 · 2022: $1,728 · 2023: $1,417 · 2024: $516 · 2025: $80.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.97 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.62 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $746.10 | 2020-2022 | |
| Amgen INC. | $703.27 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $552.46 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $541.20 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.31 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $450.40 | 2019-2024 | |
| Pfizer INC. | $379.94 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $169.10 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $133.02 | 2023 | Uptravi, Opsumit |
| Medtronic, INC. | $62.40 | 2021-2022 | |
| Shire North American Group INC | $58.55 | 2019 | |
| Abbvie INC. | $52.50 | 2021 | |
| Scpharmaceuticals INC. | $50.71 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $47.26 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.15 | 2022 | |
| Cvrx, INC. | $44.17 | 2022 | |
| Globus Medical, INC. | $41.73 | 2025 | Senza |
| Biogen, INC. | $41.48 | 2019 | |
| Amarin Pharma, INC. | $40.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $39.92 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $34.52 | 2024 | |
| Lantheus Medical Imaging, INC. | $29.74 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.44 | 2019 | |
| Allergan, INC. | $24.95 | 2020 | |
| Viiv Healthcare Company | $20.97 | 2019 | |
| Boston Scientific Corporation | $15.22 | 2021 | |
| Novo Nordisk INC | $14.22 | 2023 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2020 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.